His-Li mouse, the unique humanized mouse model resembling human liver and immune systems

Project Information

His-Li mouse

Grant agreement ID: 867383

DOI

10.3030/867383

Project closed

EC signature date 6 May 2019

Start date 1 June 2019

End date 30 September 2019

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

TRANSCURE BIOSERVICES SAS
France

Periodic Reporting for period 1 - His-Li mouse (His-Li mouse, the unique humanized mouse model resembling human liver and immune systems)

Reporting period: 2019-06-01 to 2019-09-30

Summary of the context and overall objectives of the project

Founded in 2012 and headquartered in Archamps (France), TransCure bioServices is a Contract Research Organisation (CRO) offering the best-in-class in vivo pharmacology preclinical services currently covering multiple areas of Immunology, such as Cancer/Immuno-oncology, HIV, Inflammatory Bowel Diseases and Vaccines. Their mission is to bridge the technology gap between preclinical models and human studies by developing the first and most accurate mouse model for reliable preclinical drug testing: the HIS-Li mouse platform. TransCure’s game-changing innovation is a humanized mouse model that fully reflects the human immune and liver systems. HIS-Li mouse will enable a smarter, faster and more cost-effective drug development process. The team is now focused on the optimization of the HIS-Li mouse generation protocol and the creation of disease models for therapy discovery. These models will be validated in collaboration with acknowledged pharmaceutical companies for their accuracy and reliability in preclinical testing, laying the ground for initial commercialization in Europe.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

During the feasibility assessment, TransCure defined the users’ requirements for HIS-Li mouse optimization, reviewed the development plan, defined the scale-up activities, and scouted for key stakeholders to support in the validation stages. The Company evaluated the target market segments and opportunities, defined the Total and Serviceable Addressable markets and established the commercialisation strategy. The Phase 1 feasibility assessment showed that the HIS-Li project is technically and commercially viable. The EIC Accelerator Phase 2 funding will provide an important source of non-dilutive funding to complete the planned activities.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Between 2015 and 2050, the proportion of the world's population over 60 years is projected to nearly double from 12% to 22%, reaching 2.1 B in 2050; about 434 million people will be older than 80 years. The incidence of killer diseases such as cardiovascular diseases, diabetes, respiratory diseases, etc. - mostly age-related - is expected to increase accordingly. This demographic transformation will increase demand for effective treatments, and calls for smarter drug development procedures. TransCure technology – the HIS-Li mouse – will be a uniquely efficient solution to respond to these unmet societal and medical needs by accelerating drug discovery and development, as it will enable smarter and more cost-effective market delivery of new drugs while at the same time increasing their safety. While providing huge economic benefits to the drug development industry, the HIS-Li mouse will have a wider societal impact by enabling discovery of treatments for untreatable diseases, thus contributing to saving millions of lives.

his-li-diagram.png